Skandinaviska Enskilda Banken AB publ Takes $525,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Skandinaviska Enskilda Banken AB publ bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 41,771 shares of the company’s stock, valued at approximately $525,000.

Several other hedge funds have also added to or reduced their stakes in the business. Swiss National Bank increased its holdings in shares of Day One Biopharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 117,800 shares of the company’s stock worth $1,493,000 after buying an additional 3,000 shares during the period. Essex Investment Management Co. LLC increased its stake in Day One Biopharmaceuticals by 12.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 207,574 shares of the company’s stock worth $2,630,000 after purchasing an additional 23,344 shares during the period. Jackson Creek Investment Advisors LLC bought a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $1,313,000. E Fund Management Co. Ltd. purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $143,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company’s stock worth $6,785,000 after purchasing an additional 28,053 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. HC Wainwright lowered their price objective on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Bank of America cut their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $34.57.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $8.67 on Tuesday. The firm has a 50-day moving average of $11.28 and a 200 day moving average of $12.96. The company has a market cap of $878.75 million, a P/E ratio of -8.42 and a beta of -1.38. Day One Biopharmaceuticals, Inc. has a 1 year low of $7.88 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. On average, equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.